Accession Number:

AD1095964

Title:

Wnt/Beta-Catenin, Foxa2, and CXCR4 Axis Controls Prostate Cancer Progression

Descriptive Note:

Technical Report,01 Jul 2012,30 Jun 2019

Corporate Author:

Louisiana State University Health Sciences Center SHREVEPORT United States

Personal Author(s):

Report Date:

2019-09-01

Pagination or Media Count:

154.0

Abstract:

The development of metastasis to the bone is the most dangerous complication of advanced prostate cancer PCa, frequently resulting in significant pain. Androgen deprivation therapy is the gold standard treatment for metastatic PCa patients. However, prostate tumors become resistant to hormone ablation therapy and tumors begin to grow again. The purpose of this research is to identify mechanisms that promote metastatic castrate-resistant prostate cancer progression with the ultimate goal of finding new ways to treat patients with advanced PCa. The Wntbeta-Catenin signaling pathway is a mechanism cancer cells use to communicate with their environment and to grow after androgen deprivation. Our previous research indicates the existence of an axis of Wntbeta-Catenin, FOXA2, and CXCR4. In this study, we investigated their functional implication in PCa. We found that Wntbeta-Catenin signaling is active in advanced PCa. FOXA2, a downstream target of Wntbeta-Catenin, is important for the establishment of PCa bone metastasis. Further, we found that FOXA2 regulates the expression of PTHrP and integrin alpha 1, promoting PCa bone colonization. Furthermore, we found FOXA2 sustains AR signaling after androgen deprivation, providing a mechanism for castrate-resistant growth of PCa cells. Taken together, our study revealed a critical role of Wntbeta-Catenin signaling and FOXA2 in PCa bone metastases.

Subject Categories:

  • Medicine and Medical Research
  • Genetic Engineering and Molecular Biology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE